Marine sponges are a major component of benthic communities and act as a reservoir for microbial species. In terms of biomass, they are the richest source of secondary metabolite production, with the potential to influence both benthic and pelagic systems. In most cases it is the sponge-associated microbes that account for many of the secondary metabolites assigned to the host. Here we report the occurrence of cycloaspeptide A, a fungus-derived cyclic peptide, in a culturable bacterium Salinispora arenicola. We have also identified nazumamide A, a sponge-derived linear tetrapeptide currently used as a thrombin inhibitor, in Salinispora pacifica. Their structures were determined using an integrated approach consisting of: (1) HPLC-UV-Vis-QToF-MS analysis with multimode ionization (ESI and APCI) and fast polarity switching; (2) database searching and matching of monoisotopic masses, retention times, mass spectra of the precursor and product ions of the compounds of interest and the authentic reference standards thereof.
The obligate marine actinobacterial genus Salinispora, has proven to be a trusted source of valuable secondary metabolites with several bioactivities, such as anticancer [1a] and antibiotic [1b] properties. In recent years a growing number of Salinispora-derived natural products have been isolated, including salinosporamide A, rifamycins, saliniketals and cyclomarins [1c] .
Fungi continue to be an exciting source of novel active molecules for pharmaceutical research. Cycloaspeptide A was first isolated from a mycelial chloroform extract of Aspergillus sp. NE-45 [2] . By 2006, this compound had also been isolated from four Penicillum species, two of them being psychrotolerant with high chemical diversity [3] . To date, six cycloaspeptides (A-G) have been isolated from different fungi [2,3,4a] . Among them cycloaspeptide A, a member of the anthranilic acid (ABA)-containing cyclic peptides, that has been isolated from psychrotolerant Penicillium and Aspergillus sp. NE-45 [3] .
Sponges are major components of benthic communities and among the richest source of secondary metabolites isolated from marine environments [4b] . Interest in sponge-associated bacteria has been increasing since several studies have proved that the real producer of some of these bioactive compounds, initially thought to be produced by marine sponges, are symbiotic microorganisms [4c]. For example, nazumamide A, a potent thrombin-inhibiting linear peptide, was first isolated from the marine sponge Theonella sp [4d] . In this present study, we describe the search for bioactive compounds from the obligate marine actinobacterium Salinispora, during which two peptides, nazumamide A and cycloaspeptide A were identified for the first time in this bacterium. Molecular analysis of the bacterium was based on the 16S rRNA and ribonuclease P rRNA [5a] .
Identification of Cycloaspeptide A:
In our study, HPLC-UV-Vis-QToF-MS has been used for primary screening of metabolites from two Salinispora species. Ethyl acetate extracts of the bacterium grown on agar plates were examined by a rapid mass spectrometric fingerprinting technique using HPLC-UV-Vis-QToF-MS. The advantages of this technique are its high sensitivity, rapid acquisition time and ability to detect compounds with less than 2 ppm mass accuracy from a small sample volume (20 µL).
During the investigation of the S. arenicola extract we found several peaks in the HPLC-UV chromatogram obtained using a Diode Array Detector (DAD), as shown in Supplementary Figure  1A . The major peaks found in the chromatogram were identified as saliniketals and rifamycins (data not shown) while there were some other unknown compounds, one of which was X. The UV spectrum of X shows λ max at 280 nm.
The total ion current (TIC) LC-MS chromatogram of the extract showed peak X eluting at 22.35 min ( Supplementary Figure 2 ). X was identified as cycloaspeptide A on the basis of its accurate mass using an in-house database search. The monoisotopic mass of X was 642.3301 [M+H] + (641.3213 [M] ) and that of cycloaspeptide A in the database was 641.3213 [M] . The LC-MS chromatogram and the mass spectrum of cycloaspeptide A standard further strengthened the identification of X from the database search. A cycloaspeptide A peak was absent from the blank extracts of sterile medium. For additional confirmation of the identity, the standard and sample ( Supplementary Figures 3A and 3B ) mass spectra were monitored using MS-MS fragmentation mode. The similarities in fragmentation patterns further confirm the identity of cycloaspeptide A. In MS-MS mode, 642.3283 (M+H) + was selected as the precursor ion and the presence of fragments at m/z 352, 452, 297 and 233 in this study and in a previous study [5b] confirmed the identification of cycloaspeptide A in Salinispora extracts.
Identification of nazumamide A: The unknown peak Y (Supplementary Figure 1B) , eluted at 4 min, showed UV NPC Natural Product Communications Figure 4) . Both the retention times and accurate mass spectra of the extract and the standard match, confirming the identity of peak Y in the S. pacifica extract as nazumamide A. For additional confirmation, the sample and standard were analyzed using MS-MS mode: fragmentation of the molecular ion at m/z 605 (nazumamide A) was monitored. The results for Salinispora extracts and standards are shown in Supplementary Figures 5A and 5B . Both the Salinispora extracts and standards showed marked similarity in terms of their fragmentation pattern, further confirming the identity of nazumamide A In summary, the confirmation of the identity was based on several observations: matching the monoisotopic mass with the database entry for the compound of interest; matching the retention time, UV-Vis spectra, accurate mass spectra and fragmentation spectra with the standard compound.
Out of 20 S. arenicola strains screened in this study, only two strains produced detectable concentrations of cycloaspeptide A. Out of 25 S. pacifica strains screened, only one produced nazumamide A. Most notably, both compounds are present in their three biological replicates.
Nazumamide A was previously isolated from the marine sponge Theonella sp. In our study, we have identified this compound from S. pacifica associated with the sponge Cinachyrella. There is considerable debate as to whether sponges, their symbionts, or both are responsible for the production of secondary metabolites [4b] .
We speculate that the previously identified nazumamide A was of bacterial origin; further studies are required to confirm the lateral gene transfer of the gene clusters required to encode the production of this compound.
Mitova and co-workers identified both cyclotetrapeptides and cycloaspeptides from the marine bacterium Pseudomonas spp. [5c]. Cycloaspeptide A was previously identified from Aspergillus spp., and Penicillium spp. It was surprising to identify this compound in Salinispora arenicola. One explanation may be horizontal gene transfer (HGT) between two adjacent species. It is known that sponges act as a reservoir for microbial species and there is ongoing competition between adjacent species; the possibility of gene transfer between two species exists and this may confer an adaptive benefit, allowing them to survive in a particular environment. In previous studies, it was reported that S. arenicola produced compounds which have been previously reported in other bacterial species [1a] . Except for the cyclomarins, these sets of compounds were previously described only in depsipeptides from the fungi Paecilomyces lilacinus and Biploris zeicolai [5d]. However, this is the first report of the production of cycloaspeptide A in bacteria, in this case specifically S. arenicola.
Experimental
General experimental procedure: Twenty strains (each with 3 biological replicates) of Salinispora arenicola and 25 strains (each with biological replicates) of S. pacifica were used in this study. Isolation and taxonomical identification of Salinispora isolates were performed according to published procedures [5a] . Cultivation in the laboratory, harvesting and extraction procedures are as described previously [5e]. Cycloaspeptide A was purchased from TOCRIS Bioscience, Canada. Nazumamide A was purchased from Shanghai Mocell Biotech Co., Ltd, China.
HPLC-MS-UV data acquisition:
HPLC-MS (/MS) and UV analysis was performed as in previous studies [5e] except for the variations in gradient. For the cycloaspeptide A study, the gradient used was: 20% to 55% B for the first 20 min, 55% to 100% B from 20 to 23 min and held at 100% B from 23 to 30 min. The composition of the eluent was then restored to 20% B within 3 min and the system was re-equilibrated for 10 min. For the nazumamide A study, the gradient used was: 20% to 100% B for the first 40 min, maintained at 100% B for 3 min and back to 20% B during the next 5 min and equilibrating at 20% B for 12 min.
Supplementary data: LC-UV data ( Supplementary Figure 1) , LC-MS data for cycloaspeptide A and nazumamide A ( Supplementary  Figures 2 and 4) and LC-MS/MS data for cycloaspeptide A and nazumamide A ( Supplementary Figures 3 and 5 ).
